Risk Factors of Anxiety and Depression in Patients With Herpes Zoster Neuralgia

Recruiting

• Conditions: Herpes Zoster

• Registration Number: NCT06449547
• Lead Sponsor: Huazhong University of Science and Technology

Brief Summary

The goal of this observational study is to explore risk factors of anxiety and depression in patients with herpes zoster neuralgia, and the changes of certain serum biomarkers and functional brain magnetic resonance images of these patients.

Detailed Description

Patients with herpes zoster neuralgia will be recruited and take Hospital anxiety depression rating scale (Hospital anxiety and 'scale, HADS) evaluation. According to the HADS Scores, patients will be divided into depression group and no depression, or anxiety group and no anxiety group. The clinical data the of two groups will be collected and statistically analyzed to explore the risk factors of anxiety and depression, including the changes of serum biomarkers and functional brain magnetic resonance imaging in patients with herpes zoster neuralgia accompanying anxiety or depression.

Study Timeline

• Study First Submitted: 2024-05-19
• Study First Submitted QC: 2024-06-07
• Study First Posted: 2024-06-10
• Study Start: 2024-06-21
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-23
• Last Update Posted: 2024-08-26
• Primary Completion: 2026-05
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

1. Age more than 18 years old
2. Diagnosed as herpes zoster neuralgia
3. Signing informed consent

Exclusion Criteria

1. Unable to complete the scale assessment
2. History of mental illness

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HADS score	during hospital stay, average of 1 week	Enrolled patients will be first evaluated by Hospital Anxiety and Depression Scare questionaire and according to the HADS score, patients will be divided to group with anxiety/depression and group without anxiety/depression.

Secondary Outcome Measures

Name	Time	Method
Interleukin (IL）-1β plasma level	during hospital stay, average of 1 week	Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-1β （pg/ml）will be tested.
C-reactive protein (CRP) plasma level	during hospital stay, average of 1 week	Blood sample will be obtained from enrolled patients and the plasma level of CRP（mg/ml）will be tested.
Area under curve (AUC) of topological metrics of functional brain magnetic resonance imaging	during hospital stay, average of 1 week	Functional brain magnetic resonance imaging will be performed in patients with anxiety or depression, and area under curve (AUC) of topological metrics including Eglob,Eloc,Cp,Lp,γ,λ and σ will be calculated and analyzed.
IL-2 receptor plasma level	during hospital stay, average of 1 week	Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-2 （u/ml）will be tested.
IL-10 plasma level	during hospital stay, average of 1 week	Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-10 （pg/ml）will be tested.
Interferon(INF)-α plasma level	during hospital stay, average of 1 week	Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines INF-α （pg/ml）will be tested.
IL-8 plasma level	during hospital stay, average of 1 week	Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-8 （pg/ml）will be tested.
IL-6 plasma level	during hospital stay, average of 1 week	Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-6 （pg/ml）will be tested.
Brain-derived neurotrophic factor (BDNF) plasma level	during hospital stay, average of 1 week	Blood sample will be obtained from enrolled patients and the plasma level of BDNF（pg/ml）will be tested.

Trial Locations

Locations (1)

Tongji hospital; 🇨🇳 Wuhan, Hubei, China